CSBio CSBio

X
[{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Theratechnologies"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Theratechnologies"},{"orgOrder":0,"company":"Jay Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMERI Holdings Amalgamation Partner Jay Pharma Reports IRB Approval For Testing Proprietary CBD Formulation In Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Jay Pharma"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Essa Pharma"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$891.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zymeworks Announces New Multispecific Antibody Collaboration with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Zymeworks"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma Signs an Agreement with a Montreal-based Company to Advance the Development of Adva-27a Anticancer Compound","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Sunshine Biopharma"},{"orgOrder":0,"company":"Symvivo","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Symvivo Corporation Announces Research Collaboration With Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Symvivo"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ESSA Pharma Inks Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination in Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Essa Pharma"},{"orgOrder":0,"company":"Notch Therapeutics","sponsor":"Allogene Therapeutics","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Notch Therapeutics"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of ADVA-27A in Canada until 2033","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Sunshine Biopharma"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Jefferies and Piper Sandler","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Essa Pharma"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a in Europe Until 2033","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Sunshine Biopharma"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ESSA Pharma Inks Collaborates with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Essa Pharma"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma\u2019s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Sunshine Biopharma"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Algernon Pharmaceuticals"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ExCellThera and Astellas Enter into a License for the Use of Molecule UM171 in the Field of Pluripotent Stem Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"ExCellThera"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Essa Pharma"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Presents at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics to Present at the 6th Biennial Canadian Cancer Research Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"St. Baldrick\u2019s Foundation","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rakovina Therapeutics Partners with St. Baldrick\u2019s Foundation to Research and Develop New Treatments for Childhood Bone Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference Sarcomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Briacell Advances Preparatory Work for New Bria-ots\u2122 Breast Cancer Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"BriaCell Therapeutics"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma\u2019s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sunshine Biopharma"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Presents Development Details of Bria-OTS Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"BriaCell Therapeutics"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR) Annual General Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sunshine Biopharma"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Procare Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"International Patent Application Filed for Cervical Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Biovaxys"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"University of Wisconsin\u2013Madison","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"BriaCell Therapeutics"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale up Genomic Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Precision NanoSystems"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Essa Pharma"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Announces Preclinical Data Presentation at the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase \u00ae Closes Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Theralase Technologies"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sunshine Biopharma"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces New Patent Issuance, Bria-OTS IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"BriaCell Therapeutics"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Jewish General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Sunshine Biopharma"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$484.7 million","upfrontCash":"$18.0 million","newsHeadline":"Daiichi and Zymeworks End Antibody Pact After Seven Years","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Zymeworks"},{"orgOrder":0,"company":"Andira Pharmaceuticals","sponsor":"University of British Columbia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Andira Advances Lead Cannabinoid Compositions for Metastatic Breast Cancer through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Andira Pharmaceuticals"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Radiant Biotherapeutics"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Rakovina Therapeutics"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS\u2122 Immunotherapy for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"BriaCell Therapeutics"},{"orgOrder":0,"company":"Phenomic AI","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Phenomic AI"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Repare Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The collaboration will explore the synergy between Debio 0123, a potential best-in-class, brain-penetrant, and highly selective WEE1 inhibitor, and RP-6306 (lunresertib), a first-in-class, selective and potent oral, small molecule inhibitor of PKMYT1 with anticancer activity.

            Lead Product(s): Debio 0123,Lunresertib

            Therapeutic Area: Oncology Product Name: Debio 0123

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Debiopharm

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 04, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, Phenomic and Astellas will explore the ability of antibodies, developed by Phenomic and directed at a novel target of the tumor stroma identified with Phenomic’s scTx platform, to enhance cell therapy approaches for the treatment of solid tumors.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Astellas Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company intends to use the funds for the development of Bria-OTS™, BriaCell’s novel personalized off-the-shelf immunotherapies for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma.

            Lead Product(s): Bria-OTS

            Therapeutic Area: Oncology Product Name: Bria-OTS

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: National Cancer Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding August 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Rakovina will advance its lead kt-3000 program toward human clinical trials. kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand repair mechanisms while enhancing PARP inhibitor activity.

            Lead Product(s): kt-3000

            Therapeutic Area: Oncology Product Name: kt-3000

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing May 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will advance and validate Radiant's Multabody platform among several oncology programs. Radiant’s Multabody platform exploits avidity - stronger binding power - coupled with multi-specificity to deliver highly efficacious antibodies.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amplitude Ventures

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Financing April 25, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the collaboration, Andira will advance lead Cannabinoid compositions for metastatic breast cancer with University of British Columbia. Cannabinoids slow cancer cell proliferation, generate cancer cell apoptosis and prevent angiogenesis in breast cancer.

            Lead Product(s): Cannabinoid

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: University of British Columbia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funding will support the development of assays and animal models for evaluation of the Company’s novel classes of DNA-damage response inhibitors with selection of one or more lead compounds for advancement to toxicology, including kt-3000 series dual PARP-HDAC inhibitors.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: NRC IRAP

            Deal Size: $0.1 million Upfront Cash: Undisclosed

            Deal Type: Funding March 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Zymeworks and Daiichi Sankyo entered into the Collaboration Agreement to research, develop and commercialize one bispecific antibody generated through the use of Zymeworks BC’s Azymetric and EFECT platforms.

            Lead Product(s): Bispecific Antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Daiichi Sankyo

            Deal Size: $484.7 million Upfront Cash: $18.0 million

            Deal Type: Termination March 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through IND-enabling studies. At any time the research results become conclusive, company will proceed to conducting a Phase I clinical trial.

            Lead Product(s): Adva-27a

            Therapeutic Area: Oncology Product Name: Adva-27a

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jewish General Hospital

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Development of Rakovina Therapeutics’ novel kt-3000 bi-functional DNA-damage response inhibitors is supported, by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma.

            Lead Product(s): KT-3000

            Therapeutic Area: Oncology Product Name: KT-3000

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 26, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY